MELANIE NELSON: Open Payments
NPI 1124750096 · BOUNTIFUL, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$611 in 30 payments from 9 companies in 2025. Trend: 2023 $192 · 2024 $1,180 · 2025 $611
Food & beverage: $548Education: $63
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 18 | $313 |
| SANOFI-AVENTIS U.S. LLC | 1 | $55 |
| Novartis Pharmaceuticals Corporation | 3 | $55 |
| GlaxoSmithKline, LLC. | 2 | $45 |
| AstraZeneca Pharmaceuticals LP | 2 | $40 |
| Genentech USA, Inc. | 1 | $32 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $29 |
| Blueprint Medicines Corporation | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
Products named: DUPIXENT, TRELEGY ELLIPTA, TEZSPIRE, Rhapsido, Xolair, NEFFY, AYVAKIT, CUVITRU.
Industry payments across UT — which companies pay providers there.
